Sanofi ADR (SNY) concluded trading on Thursday at a closing price of $54.15, with 4.73 million shares of worth about $256.29 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.76% during that period and on January 30, 2025 the price saw a gain of about 3.84%. Currently the company’s common shares owned by public are about 2.61B shares, out of which, 2.50B shares are available for trading.
Stock saw a price change of 4.17% in past 5 days and over the past one month there was a price change of 11.12%. Year-to-date (YTD), SNY shares are showing a performance of 12.27% which increased to 7.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $45.22 but also hit the highest price of $58.97 during that period. The average intraday trading volume for Sanofi ADR shares is 2.40 million. The stock is currently trading 7.25% above its 20-day simple moving average (SMA20), while that difference is up 10.48% for SMA50 and it goes to 5.80% higher than SMA200.
Sanofi ADR (NASDAQ: SNY) currently have 2.61B outstanding shares and institutions hold larger chunk of about 11.26% of that.
The stock has a current market capitalization of $135.14B and its 3Y-monthly beta is at 0.55. PE ratio of stock for trailing 12 months is 29.85, while it has posted earnings per share of $1.81 in the same period. Its PEG reads 2.66 and has Quick Ratio of 0.65 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SNY, volatility over the week remained 1.56% while standing at 1.34% over the month.
Stock’s fiscal year EPS is expected to rise by 14.83% while it is estimated to increase by 10.99% in next year. EPS is likely to grow at an annualized rate of 11.21% for next 5-years, compared to annual growth of 2.68% made by the stock over the past 5-years.
Coverage by Argus stated Sanofi ADR (SNY) stock as a Buy in their note to investors on July 26, 2024, suggesting a price target of $60 for the stock. Stock get a Neutral rating from JP Morgan on December 05, 2023.
